交易 UroGen Pharma Ltd. - URGN 差价合约

交易条件

• 类型: 差价合约
• 点差: 0.08
• 长仓隔夜仓息调整: -0.02157%
• 短仓隔夜仓息调整: -0.00065%
• 隔夜调整仓息时间: 22:00 (UTC)
• 货币: USD
• 最低成交量: 1
• 保证金: 5.00%
• 证券交易所: United States of America
• 交易佣金: 0%
• 保证止损溢价: 1%

主要统计数据

• 前收盘价: 20.48
• 开仓: 20.96
• 1 年变化: 58.19%
• 日区间: 20.46 - 21.58

UroGen Pharma Ltd. (NASDAQ: URGN) is a clinical-stage biopharmaceutical company developing therapies for urothelial cancers and urologic diseases using its proprietary RTGel platform. The company’s lead asset, Jelmyto, is approved for low-grade upper tract urothelial cancer and serves as proof of concept for localized drug delivery. With additional candidates in bladder cancer, UroGen offers investors targeted exposure to niche oncology indications with a novel delivery mechanism.